Anteris Technologies Global (NASDAQ:AVR) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Anteris Technologies Global (NASDAQ:AVR) in a report issued on Thursday, MarketBeat reports. The brokerage issued an overweight rating and a $15.00 price objective on the stock.

Several other brokerages have also recently commented on AVR. Wells Fargo & Company started coverage on shares of Anteris Technologies Global in a research report on Wednesday. They set an “overweight” rating and a $16.00 price target for the company. Lake Street Capital restated a “buy” rating and issued a $15.00 price objective on shares of Anteris Technologies Global in a report on Friday, January 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anteris Technologies Global in a research note on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Anteris Technologies Global presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Anteris Technologies Global Price Performance

Anteris Technologies Global stock opened at $6.19 on Thursday. The business’s 50-day simple moving average is $5.78 and its 200 day simple moving average is $5.02. The company has a quick ratio of 0.73, a current ratio of 0.73 and a debt-to-equity ratio of 0.01. The stock has a market cap of $255.03 million, a price-to-earnings ratio of -2.42 and a beta of 1.15. Anteris Technologies Global has a 12-month low of $2.34 and a 12-month high of $7.09.

Anteris Technologies Global (NASDAQ:AVR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.75) earnings per share for the quarter. Anteris Technologies Global had a negative return on equity of 536.04% and a negative net margin of 4,921.27%.The firm had revenue of $0.31 million for the quarter. As a group, research analysts anticipate that Anteris Technologies Global will post -2.66 earnings per share for the current year.

Insider Transactions at Anteris Technologies Global

In related news, major shareholder L1 Capital Pty Ltd bought 5,000,000 shares of Anteris Technologies Global stock in a transaction on Thursday, January 22nd. The shares were purchased at an average price of $5.75 per share, for a total transaction of $28,750,000.00. Following the completion of the acquisition, the insider owned 13,219,814 shares in the company, valued at approximately $76,013,930.50. This represents a 60.83% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 4.50% of the company’s stock.

Institutional Trading of Anteris Technologies Global

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marex Group plc bought a new position in Anteris Technologies Global during the 2nd quarter worth approximately $641,000. Macquarie Group Ltd. grew its holdings in Anteris Technologies Global by 12,369.6% during the fourth quarter. Macquarie Group Ltd. now owns 33,668 shares of the company’s stock valued at $168,000 after purchasing an additional 33,398 shares during the period. Walleye Capital LLC bought a new stake in Anteris Technologies Global in the fourth quarter valued at approximately $147,000. Deutsche Bank AG increased its stake in Anteris Technologies Global by 8.1% in the fourth quarter. Deutsche Bank AG now owns 28,865 shares of the company’s stock valued at $144,000 after purchasing an additional 2,171 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Anteris Technologies Global by 34.4% in the third quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,780 shares of the company’s stock worth $71,000 after purchasing an additional 4,036 shares during the period.

About Anteris Technologies Global

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.